# US 2001/0025037 A1 · Systemic administration of a therapeutic preparation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0025037 A1
- Document ID: US20010025037A1
- Status: Published application
- Kind: A1
- Application number: 09/783,189
- Filed: 2001-02-14
- Published: 2001-09-27
- Earliest claimed: 1994-06-23
- Assignees: AstraZeneca AB
- Inventors: Kjell Goran Erik Backstrom; Carl Magnus Olof Dahlback; Peter Edman; Ann Charlotte Birgit Johansson
- Web page: https://patentgrep.com/patent/US20010025037A1

## CPC

- C07K 14/62: Insulins
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method of treating a patient in need of insulin treatment, including the steps of introducing into the lower respiratory tract of the patient an effective amount of a therapeutic preparation in the form of a dry powder containing (a) insulin and (b) an enhancer compound which enhances the absorption of insulin in the lungs of the patient.

## Claims

### Claim 1

A method of treating a patient in need of insulin treatment, comprising introducing into the lower respiratory tract of said patient an effective amount of active compounds (a) insulin and (b) a bile salt which enhances the absorption of insulin in the lower respiratory tract of said patient, which active compounds are comprised in a dry powder suitable for inhalation.

### Claim 2 (depends on 1)

The method of claim 1, wherein at least 50% of the total mass of said active compounds in said powder, at the point of introduction into the respiratory system of said patient, consists of particles having a diameter of about 10 microns or less.

### Claim 3 (depends on 2)

The method of claim 2, wherein said powder is supplied as agglomerates of said particles of said active compounds contained in an inhaler device, said agglomerates being substantially deagglomerated prior to entry into the respiratory system of said patient.

### Claim 4 (depends on 2)

The method of claim 2, wherein the powder is supplied as an ordered mixture of particles of active substance having a diameter of about 10 microns or less and particles of a carrier substance additionally comprised in said powder, contained in an inhaler device.

### Claim 5 (depends on 3)

The method of claim 3, wherein said particles are inhaled by said patient from said inhaler device, said agglomerates being substantially deagglomerated by air turbulence in said inhaler device.

### Claim 6 (depends on 2)

The method of claim 2, wherein said patient inhales said powder from a single-dose, dry powder inhaler device.

### Claim 7 (depends on 1)

The method of claim 1, wherein said insulin is human insulin.

### Claim 8 (depends on 1)

The method of claim 1, wherein said bile salt is a trihydroxy bile salt.

### Claim 9 (depends on 1)

The method of claim 1, wherein said bile salt is a salt of cholic, glycocholic, or taurocholic acid.

### Claim 10 (depends on 1)

The method of claim 1, wherein said bile salt is a sodium or potassium salt of cholic acid.

### Claim 11 (depends on 1)

The method of claim 1, wherein said bile salt is a sodium or potassium salt of glycocholic acid.

### Claim 12 (depends on 1)

The method of claim 1, wherein said bile salt is sodium taurocholate.

### Claim 13 (depends on 1)

The method of claim 1, wherein said bile salt is potassium taurocholate.

### Claim 14 (depends on 1)

The method of claim 1, wherein said bile salt is a salt of chenodeoxycholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, deoxycholic acid, glycodeoxycholic acid, taurodeoxycholic acid, lithocholic acid, or ursodeoxycholic acid.

### Claim 15 (depends on 1)

The method of claim 1, wherein the ratio of insulin to bile salt in said powder is between about 9:1 and about 1:1.

### Claim 16 (depends on 1)

The method of claim 1, wherein at least 50% of the total mass of said active compounds is in the form of particles which have a diameter of 10 microns or less, or of agglomerates of said particles.

### Claim 17

A method of treating a patient in need of insulin treatment, comprising introducing into the lower repiratory tract of the patient a dry powder pharmaceutical preparation comprising active compounds (a) insulin and (b) a bile salt which enhances the systemic absorption of insulin in the lower respiratory tract of said patient, said preparation being in the form of a dry powder in which at least 50% of the total mass of active compounds consists of particles having a diameter of about 10 microns or less, wherein the plasma pharmacokinetics of said insulin delivered by said method more closely resemble the plasma pharmacokinetics of endogenous insulin secreted by a healthy individual in response to a glucose challenge, than do the plasma pharmacokinetics of human insulin delivered by subcutaneous injection.

### Claim 18 (depends on 17)

The method of claim 17, wherein said bile salt is a trihydroxy bile salt.

### Claim 19 (depends on 17)

The method of claim 17, wherein said bile salt is a salt of cholic, glycocholic, or taurocholic acid.

### Claim 20 (depends on 17)

The method of claim 17, wherein said bile salt is a sodium or potassium salt of cholic acid.

### Claim 21 (depends on 17)

The method of claim 17, wherein said bile salt is a sodium or potassium salt of glycocholic acid.

### Claim 22 (depends on 17)

The method of claim 17, wherein said bile salt is sodium taurocholate.

### Claim 23 (depends on 17)

The method of claim 17, wherein said bile salt is potassium taurocholate.

### Claim 24 (depends on 17)

The method of claim 17, wherein said bile salt is a salt of chenodeoxycholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, deoxycholic acid, glycodeoxycholic acid, taurodeoxycholic acid, lithocholic acid, or ursodeoxycholic acid.

### Claim 25 (depends on 17)

The method of claim 17, wherein the ratio of insulin to bile salt in said powder is between about 9:1 and about 1:1.

### Claim 26 (depends on 17)

The method of claim 17, wherein said patient inhales said powder from a single-dose, dry powder inhaler device.

### Claim 27

A method of treating a patient in need of insulin treatment, comprising introducing into the lower respiratory tract of said patient an effective amount of active compounds (a) insulin and (b) a substance which enhances the absorption of insulin in the lower respiratory tract of said patient, which active compounds are comprised in a dry powder suitable for inhalation, provided that said substance is selected from the group consisting of a C8-C16 fatty acid, a salt of such a fatty acid, a salt of glycyrrhizine acid, an acyl carnitine, a phospholipid, and an alkyl saccharide.

### Claim 28 (depends on 27)

The method of claim 27, wherein the therapeutic preparation contains only said active compounds.

### Claim 29 (depends on 27)

The method of claim 27, wherein the dry powder contains, in addition to said active compounds, a pharmaceutically acceptable carrier.

### Claim 30 (depends on 27)

The method of claim 27, wherein said substance is a sodium, potassium or lysine salt of caprylic acid (C8), capric acid (C10), lauric acid (C12), or myristic acid (C14).

### Claim 31 (depends on 27)

The method of claim 27, wherein said substance is a single- or double-chain phospholipid.

### Claim 32 (depends on 27)

The method of claim 27, wherein said substance is selected from the group consisting of lysophosphatidylcholine, lysophosphatidylglycerol, lysophosphatidylethanolamine, lysophosphatidylinositol, lysophosphatidylserine, diacylphosphatidylcholine, diacylphosphatidylglycerol, diacylphosphatidylethanolamine, diacylphosphatidylinositol, and diacylphosphatidylserine.

### Claim 33 (depends on 27)

The method of claim 27, wherein said substance is palmitoylphosphatidylglycerol, palmitoylphosphatidylcholine, dioctanoylphosphatidylglycerol or dioctanoylphosphatidylcholine.

### Claim 34 (depends on 27)

The method of claim 27, wherein said substance is an alkyl glucoside or alkyl maltoside.

### Claim 35 (depends on 27)

The method of claim 27, wherein said substance is decyl glucoside, dodecyl glucoside, decyl maltoside, or dodecyl maltoside.

### Claim 36 (depends on 27)

The method of claim 27, wherein said substance is a sodiu or potassium salt of glycyrrhizine acid.

### Claim 37 (depends on 27)

The method of claim 27, wherein said substance is decanoyl carnitine, lauryl carnitine, myristoyl carnitine, or palmitoyl carnitine.

### Claim 38 (depends on 27)

The method of claim 27, in which at least 50% of the dry powder consists of (a) particles having a diameter of between 1 and 6 microns or (b) agglomerates of such particles.

### Claim 39 (depends on 27)

The method of claim 27, wherein the ratio of (A) to (B) in said preparation is in the range of 9:1 to 1:1.
